These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37539130)

  • 1. The role of microbial metabolites in diabetic kidney disease.
    Zhu T; Hu BY; Zhang YQ; Zhang ZY; Cai KW; Lei L; Hu B; Wang XH; Tang C; Lu YP; Zheng ZH
    Heliyon; 2023 Jul; 9(7):e17844. PubMed ID: 37539130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis".
    Han C; Shen Z; Cui T; Ai SS; Gao RR; Liu Y; Sui GY; Hu HZ; Li W
    J Ethnopharmacol; 2023 May; 307():116257. PubMed ID: 36787845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Gut Microbiota and Microbiota-Related Serum Metabolites in the Progression of Diabetic Kidney Disease.
    Zhang Q; Zhang Y; Zeng L; Chen G; Zhang L; Liu M; Sheng H; Hu X; Su J; Zhang D; Lu F; Liu X; Zhang L
    Front Pharmacol; 2021; 12():757508. PubMed ID: 34899312
    [No Abstract]   [Full Text] [Related]  

  • 4. Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism.
    Chen DQ; Zhang HJ; Zhang W; Feng K; Liu H; Zhao HL; Li P
    Exp Gerontol; 2024 Apr; 188():112393. PubMed ID: 38458480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease.
    Lu YP; Zhang ZY; Wu HW; Fang LJ; Hu B; Tang C; Zhang YQ; Yin L; Tang DE; Zheng ZH; Zhu T; Dai Y
    J Transl Med; 2022 Sep; 20(1):420. PubMed ID: 36104729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice.
    Wu J; Chen Y; Yang H; Gu L; Ni Z; Mou S; Shen J; Che X
    Front Endocrinol (Lausanne); 2023; 14():1026040. PubMed ID: 36777358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between Plasma Metabolomics and Intestinal Microbiome in db/db Mouse, an Animal Model for Study of Type 2 Diabetes and Diabetic Kidney Disease.
    Wu C; Fei J; Xu Q; Tao Y; Zhou Z; Wang Y; Wu J; Gu HF
    Metabolites; 2022 Aug; 12(9):. PubMed ID: 36144180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astragalus membranaceus and Salvia miltiorrhiza ameliorate diabetic kidney disease via the "gut-kidney axis".
    Shen Z; Cui T; Liu Y; Wu S; Han C; Li J
    Phytomedicine; 2023 Dec; 121():155129. PubMed ID: 37804821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis.
    Li L; Wei T; Liu S; Wang C; Zhao M; Feng Y; Ma L; Lu Y; Fu P; Liu J
    J Cell Mol Med; 2021 Jan; 25(2):960-974. PubMed ID: 33280239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome-metabolome combined validation in a mouse model.
    Shang J; Cui W; Guo R; Zhang Y; Wang P; Yu W; Zheng X; Wang T; Dong Y; Zhao J; Ding S; Xiao J; Ren Z; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():964389. PubMed ID: 36601003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models.
    Jiang Y; Cui W; Zhang Y; Wang T; Zheng X; Li H; Shang J
    Front Physiol; 2023; 14():1195441. PubMed ID: 37654676
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease.
    Ma L; Zhang L; Li J; Zhang X; Xie Y; Li X; Yang B; Yang H
    Mol Med; 2023 Oct; 29(1):148. PubMed ID: 37907885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary microbiota and serum metabolite analysis in patients with diabetic kidney disease.
    Yang Y; Ma C; Li S; Cai W; Dai W; Zhang X; Yin L; Donge Tang ; Liu F; Dai Y
    Heliyon; 2023 Aug; 9(8):e17040. PubMed ID: 37521000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.
    Mao ZH; Gao ZX; Liu DW; Liu ZS; Wu P
    Front Immunol; 2023; 14():1124704. PubMed ID: 36742307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Serum Metabolites and Gut Microbiota in Diabetic Kidney Disease.
    Zhang B; Wan Y; Zhou X; Zhang H; Zhao H; Ma L; Dong X; Yan M; Zhao T; Li P
    Front Pharmacol; 2022; 13():872988. PubMed ID: 35548353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic Signature of Diabetic Kidney Disease in Cerebrospinal Fluid and Plasma of Patients with Type 2 Diabetes Using Liquid Chromatography-Mass Spectrometry.
    Lin HT; Cheng ML; Lo CJ; Lin G; Liu FC
    Diagnostics (Basel); 2022 Oct; 12(11):. PubMed ID: 36359470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
    Zhong C; Dai Z; Chai L; Wu L; Li J; Guo W; Zhang J; Zhang Q; Xue C; Lin H; Luo Q; Cai K
    J Clin Lab Anal; 2021 Dec; 35(12):e24062. PubMed ID: 34689373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PM
    Jiang Y; Peng Y; Yang X; Yu J; Yu F; Yuan J; Zha Y
    PeerJ; 2023; 11():e15856. PubMed ID: 37671359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
    Hu Y; Tang W; Liu W; Hu Z; Pan C
    Drug Des Devel Ther; 2022; 16():1605-1620. PubMed ID: 35669284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
    Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN
    Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.